Trials / Withdrawn
WithdrawnNCT03239236
Modified Rapid Sequence Induction in Morbidly Obese Patients
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the effect of 4 different methods of rapid sequence induction (RSI) in morbidly obese patients on the amount of air insufflation into the stomach.
Detailed description
100 adult patients with a body mass index \> 40 undergoing elective laparoscopic surgery will be included. Patients with a history of previous bariatric surgery or with an anticipated difficult airway will be excluded. The randomization will be 1:1:1:1 stratified for gastro-esophageal reflux disease. All groups will receive standardized preoperative continuous positive airway pressure (CPAP) therapy. In the operation theater, Group one will receive pre-oxygenation for 3 minutes via a tight fitting face mask without positive end-expiratory pressure (PEEP). Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight) and tracheal intubation will be performed after 1 minute. No bag mask ventilation will be performed in-between. Group 2 will receive pre-oxygenation via a tight face mask with a PEEP of 10 mbar for 3 minutes. The same induction agents as in group one will be administered. PEEP via facemask will be continued for one minute and tracheal intubation will be performed. Group 3 will receive pre-oxygenation via a tight fitting facemask with a PEEP of 10 mbar with additional pressure support of 8 mbar and a back up ventilation frequency will be set to 10/min. After the same induction agents are given as in group 1, patients will receive non-invasive ventilation via ventilator at the settings described earlier for group 3. Group 4 will receive the same induction as group 3, in addition a cricoid pressure will be applied during the non invasive ventilation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Rapid sequence induction t-RSI | Preoxygenation via face mask, no ventilation with no PEEP until intubation |
| PROCEDURE | Rapid sequence induction m-RSI-PEEP | Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation. |
| PROCEDURE | Rapid sequence induction m-RSI-vent | Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation. |
| PROCEDURE | m-RSI-vent-cric | Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation. |
| PROCEDURE | Cricoid Pressure | Cricoid Pressure will be applied during RSI until laryngoscopy |
| DRUG | Anesthetics | Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight). |
| DIAGNOSTIC_TEST | Aspiration of gastric air via nasogastric tube | A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml. |
| DIAGNOSTIC_TEST | Impression of gastric inflation at laparoscopy. | The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded. |
| DIAGNOSTIC_TEST | Arterial blood gas | Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated. |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2021-02-01
- Completion
- 2021-02-01
- First posted
- 2017-08-04
- Last updated
- 2021-02-18
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT03239236. Inclusion in this directory is not an endorsement.